GEA has been developing continuous manufacturing (CM) solutions for several years and helping customers to develop, evaluate and optimize continuous processing techniques to enable them to bring new products to market faster and cheaper.
At the heart of GEA’s CM solution is ConsiGma™, a multipurpose platform that has been designed to transfer powder into coated tablets in development, pilot, clinical and production volumes in a single compact unit.
At Pharmtech & Ingredients (booth #B405), GEA’s ConsiGma® 1 laboratory granulator will be on display and in operation. The ConsiGma® 1 can be fitted with an optional fluid bed dryer segment for research and development work.
Designed for maximum flexibility and simplicity during R&D and formulation development, the ConsiGma® can accommodate throughput rates as low as 5 kg/h, whereas the optional fluid bed dryer can handle volumes as low as 500 g.
- Cost-effective processing
- Less API used in R&D
- Minimized losses
- No scale-up required
- Decreased operational costs (less space, no work in progress, higher efficiency)
- Less risk
- No scale-up or tech transfer to production-scale unit
- Flexible batch size
- Fast changeover
- User-friendly controls
- Plug and play, ready to use
- Fast and easy exploration of design space
- Process parameters directly transferrable to production unit
Continuous manufacturing is gaining momentum in the pharmaceutical industry, enabling a more efficient way of making drugs and moving away from stepwise and time-consuming batch processing to a fully integrated and closely controlled process that gives excellent product consistency by intrinsic design.
Continuous production has a much smaller footprint, offers higher yields and lower environmental emissions per unit of product, leading to higher levels of sustainability. Moreover, ConsiGma™ brings Six Sigma process performance to the pharmaceutical industry.